UK 08:42 Sunday, 25 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
“Regenerative medical devices company” Tissue Regenix (TRX) announced results on 30th September including that it was “confident in the underlying business and market opportunities for our leading products and superior technology” despite also “that estimates used for 2024 year-end inventory and cost of sales were inaccurate… This is expected to be clarified in the next month and any restatement will not affect the company’s revenue numbers for FY 2024”. I though noted uncertainty and concern as well as that my ‘“remains confident of achieving profitability at the adjusted EBITDA level for the full year in line”, but how confident to really be of that?’ caution looked to remain valid and to still avoid/sell. Now an announcement; “Statement re. Suspension”!
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
